Justin Bader, Pharm.D.

Associate Director
Spero Therapeutics

Disclosure(s): No financial relationships to disclose

Poster(s):

• 1695 - Combination Therapy for the Investigational Polymyxin SPR206 and Meropenem (MEM) Increases the Rapidity and Extent of Killing of Pseudomonas aeruginosa (PA) and Prevents the Bacterium from Emerging Resistant to Both Antibiotics
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET